Combination antimicrobial therapy for bacterial infections. Guidelines for the clinician

Drugs

Volumn 52, Issue 3, 1996, Pages 390-405

  Rybak, Michael J ^a,b,d   McGrath, Betty J ^c,d  

^a DETROIT RECEIVING HOSPITAL   (United States)

^b Anti Infective Research Laboratory   (United States)

^c Grace Hospital   (United States)

^d WAYNE STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMPICILLIN; ANTIINFECTIVE AGENT; BETA LACTAM ANTIBIOTIC; CEPHALOSPORIN; CLINDAMYCIN; GENTAMICIN; LATAMOXEF; METRONIDAZOLE; PIPERACILLIN; VANCOMYCIN;

ACINETOBACTER; ANTIBIOTIC RESISTANCE; ANTIMICROBIAL THERAPY; BACTERIAL INFECTION; BLOOD CLOTTING DISORDER; CITROBACTER; DIARRHEA; DRUG COST; DRUG HYPERSENSITIVITY; ENTEROBACTER; ENTEROCOCCUS; GRANULOCYTOPENIA; HUMAN; NEPHROTOXICITY; PRACTICE GUIDELINE; PSEUDOMONAS AERUGINOSA; REVIEW; SEIZURE; SERRATIA; STAPHYLOCOCCUS AUREUS;

EID: 0029815534     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199652030-00005     Document Type: Review

References (110)

1. Moellering RC. Principles of antiinfective therapy. In: Mandell GL, Douglas RG, Bennett GE, editors. Principals and practice of infectious diseases. 3rd ed. New York: Churchill Livingstone, 1990: 206-18
2. Freifeld AG. The antimicrobial armamentarium. In: Pizzo PA, guest editor. Infectious complications in the immunocompromised host I: Hematology/Oncology Clinics of North America. Philadelphia: WB Saunders, 1993: 813-39
3. Chastre J, Fagon JY, Trouillet JL. Diagnosis and treatment of nosocomial pneumonia in patients in intensive care units. Clin Infect Dis 1995; 21 Suppl. 3: S226-37
4. Bone RC. The pathogenesis of sepsis. Ann Intern Med 1991; 115: 457-69
5. McCracken GH, Sande MA, Lentnek A. et al. Evaluation of new anti-infective drugs tor the treatment of acute bacterial meningitis. Clin Infect Dis 1992; 15 Suppl. 1: S182-88
6. Scheld WM, Sande MA. Endocarditis and intravascular infections. In: Mandell GL, Douglas RG, Bennett GE, editors. Principals and practice of infectious diseases. 3rd ed. New York: Churchill Livingstone, 1990: 670-706
7. Moellering RC, Kunz LJ, Poitras JW. et al. Microbiologic basis for the rational use of antibiotics. South Med J 1977; 70 Suppl.: 8-15
8. Abramowicz M. The choice of antibacterial drugs. Med Let 1992; 34: 49-56
9. Schimpff SC. Therapy of infection in patients with granulocytopenia. Med Clin North Am 1978; 61: 1101-08
10. De Jongh CA, Joshi JH, Newman KA, et al. Antibiotic synergism and response in gram-negative bacteremia in granulocytopenic cancer patients. Am J Med 1986; 80: 96-100
11. Sapico FL, Witte JL, Canawati HN, et al. The infected foot of the diabetic patient: quantitative microbiology and analysis of clinical features. Rev Infect Dis 1984; 6 Suppl. 1: S171-6
12. Brismar B, Malmborg AS, Tunevall G, et al. Piperacillintazobactam versus imipenem-cilastin for treatment of intra-abdominal infections. Antimicrob Agents Chemother 1992; 36: 2766-73
13. Lorian V. Antibiotics in laboratory medicine. Laboratory methods used to assess the activity of antimicrobial combinations. 3rd ed. Baltimore: Williams & Wilkins, 1941: 434-44
14. Norden CW. Problems in determination of antibiotic synergism in vitro. Rev Infect Dis 1982; 4: 276-81
15. Rand KH, Houcj HJ, Brown P, et al. Reproducibility of the microdilution checkerboard method for antibiotic synergy. Antimicrob Agents Chemother 1993; 37: 613-5
16. Cappelletty DM, Rybak MJ. A comparison of methodologies for synergism testing against resistant strains of Pseudomonas aeruginosa. Antimicrob Agents Chemother 1996; 40: 677-83
17. Cremieux AC, Carbon C. Pharmacokinetic and pharmacodynamic requirements for antibiotic therapy of experimental endocarditis. Antimicrob Agents Chemother 1992; 36: 2064-74
18. Moellering Jr RC, Wennersten C, Weinberg AN. Synergy of penicillin and gentamicin against Enlerococci. J Infect Dis 1971; 124 Suppl. 124: S207-9
19. Moellering Jr RC, Korzeniowski OM, Sande MA, et al. Species-specific resistance to antimicrobial synergism in Streptococcus faecium and Streptococcus faecalis. J Infect Dis 1979; 140: 203-8
20. 14C-labeled streptomycin by enterococci. J Clin Invest 1971; 50: 2580-4
21. Sande MA, Scheld WM. Combination antibiotic therapy of bacterial endocarditis Ann Intern Med 1980; 92: 390-5.
22. Chandrasekar PH, Crane LR, Bailey EJ. Comparison of the activity of antibiotic combinations in vitro with clinical outcome and resistance emergence in serious infection by Pseudomonas aeruginosa in non-nentropenic patients. J Antimicrob Chemother 1987; 19: 321-9
23. Kapusnik JE, Hackbarth CJ, Chambers HF, et al. Single. large daily dosing of tobramycin for treating experimental pseudomonas pneumonia. J Infect Dis 1988; 158: 7-12
24. Hilf M, Yu VL, Sharp J, et al. Antibiotic therapy for Pseudomonas aeruginosa bacteremia: outcome correlations in a prospective study of 200 patients. Am J Med 1989; 87: 540-6
25. Pizzo PA, Hathorn JW, Hiemenz J, et al. A randomized trial comparing ceftazidime alone with combination antibiotic therapy in cancer patients with fever and neutropenia. N Engl J Med 1986; 15: 552-8
26. EORTC International Antimicrobial Therapy Cooperative Group. Efficacy and loxicity of single-daily doses of amikacin and ceftriaxone vs. multiple daily doses of amikacin and ceftazidime for infection in patients with cancer and granulocytopenia. Ann Intern Med 1993; 119: 584-43
27. Ehrhardt AF, Sanders CC. β-Lactam resistance amongst Enterobacter species. J Antimicrob Chemother 1993; 32 Suppl. B: 1-11
28. Kaatz GW, Seo SM, Barriere SL. et al. Ciprofloxacin and rifampin, alone and in combination for therapy of experimental Staphylococcus aureus endocarditis. Antimicrob Agents Chemother 1984; 33: 1184-7
29. Kang SL, Rybak MJ, McGrath BJ, et al. Pharmacodynamics of levofloxacin, ofloxacin, ciprofloxacin, alone and in combination with rifampin against methicillin-resistant Staphylococcus aureus in an in vitro infection model. Antimicrob Agents Chemother 1994; 38: 2702-9
30. Bushby SRM. Trimethoprim-sulfamethoxazole: in vitro microbiologic aspects. J Infect Dis 1973; 128: S442-62
31. Hitehings GT. The biochemical basis for the antimicrobial activity of septrin. In: Bernstein LS, Salter AJ, editors. Trimethoprim-sulfamethoxazole in bacterial infections. Edinburgh and London: Churchill Livingstone, 1973: 7-16
32. Neu HC, editor. Beta-lactamase inhibition: therapeutic advances. Am J Med 1985; 79 Suppl. 5B: 1-196
33. Leigh DA, Phillips I, Wise R. Timentin-ticarcillin plus acid: a laboratory and clinical perspective. J Antimicrob Chemother 1986; 17 Suppl. C: 1-244
34. Kuck NA, Jacobus NV, Petersen. et al. Comparative in vitro and in vivo activities of piperacillin combined with the β-lactamase inhibitors tazobactam, clavulanic acid, and sulbuctam. Antimicrob Agents Chemother 1989; 33: 1964-9
35. Goto S, Miyazaki S, Kaneko Y. The in-vitro activity of RP 59500 against gram-positive cocci. J Antimicrob Chemother 1992; 30 Suppl. A: 25-8
36. Craig WA, Gudmundsson S. Postantibiotic effect. In: Lorian V, editor. Antibiotics in laboratory medicine. 3rd ed. Baltimore: Williams and Wilkins, 1991: 403-31
37. Bundtzen RW, Gerber AU, Cohn DL, et al. Postantibiotic suppression of bacterial growth. Rev Infect Dis 1981; 3: 28-37
38. Odenholt-Tornqvist I. Studies on the postantibiotic effect and the postantibiotic sub-MIC effect of nieropenem. J Antimicrob Chemother 1993; 31: 881-92
39. Vogelman B, Gudmundsson S, Turnidge J, et al. In vivo postantibiotic effect in a thigh infection in neutropenic mice. J Infect Dis 1988; 157: 287-98
40. Isaksson B, Hanberger H, Maller R. Synergistic post-antibiotic effect of amikacin and β-lactam antibiotics in Enterococcus faecalis. J Antimicrob Chemother 1991; 27 Suppl. C: 9-14
41. Leggett JE, Ebert S, Fantin B, et al. Comparative dose-effect relations at several dosing intervals for beta-lactams, aminoglycosides and quinolone antibiotics against gram-negative bacilli in a murine thigh infection and pneumonitis models. Scand J Infect Dis 1991; 74 Suppl.: 179-84
42. Sanders CC, Sanders Jr E. Microbial resistance to newer generation β-lactam antibiotics: clinical and laboratory implications. J Infect Dis 1985; 151: 399-406
43. Vu H, Nikaido H. Role of β-lactam hydrolysis in the mechanism of resistance of a β-lactamase-constitutive Enterobacter cloacae strain to extended spectrum β-lactams. Antimicrob Agents Chemother 1985; 27: 393-8
44. Miller MA, Finan M, Yousuf M. In vitro antagonism by N-formimidoyl thienamycin and cefoxitin of second and third generation cephalosporins in Aeromonas hydrophilia and Serratia marcescens. J Antimicrob Chemother 1983; 11: 311-8
45. Calderwood SB, Gardella A, Philippon AM, et al. Effects of azlocillin in combination with clavulanic acid, sulbactam, and N-fortmimidoyl thienamycin against β-lactamase-producing, carbenecillin-resistant Paeudomonas aeruginosa. Antimicrob Agents Chemother 1982; 22: 266-71
46. Gutmann L, Williamson R, Kitzis M, et al. Synergism and antagonism in double beta-lactam combinations. Am J Med 1986; 80 Suppl. 5C: 21-9
47. Winston DJ, Barnes DC, Ho WG, et al. Moxalactam plus piperacillin versus moxalactam plus amikacin in febrile granulocytopenic patients. Am J Med 1984; 77: 442-50
48. Moellering RC, Eliopoulos GM, Allan JD. Beta-lactam aminoglycoside combinations interactions and their mechanisms. Am J Med 1986; 80 Suppl. 5C: 30-4
49. Pickering LK, Rutherford I. Effect of concentration and time upon the inactivation of tobramycin. gentamicin. netilmicin and amikacin by azlocillin, carbenecillin, mecillinam, mezlocillin and piperacillin. J Pharmucol Exp Ther 1981; 217: 345-9
50. Rybak MJ, Albrecht, Boike SC, et al. Nephrotoxicity of vancomycin, alone and with an aminoglycoside. J Antimicrob Chemother 1990; 25: 679-87
51. Goetz MB, Sayers J. Nephrotoxicity of vancomycin and aminoglycoside therapy separately and in combination. J Antimicrob Chemother 1993; 32: 325-34
52. Tillotson JR, Finland M. Bacterial colonization and clinical superinfection of the respiratory tract complicating antibiotic treatment of pneumonia. J Infect Dis 1969; 119: 597-624
53. McGowan JE. Antimicrobial resistance in hospital organisms and its relation to antibiotic use. Rev Infect Dis 1983; 5: 1033-48
54. Wey SB, Mori M, Pfaller MA, et al. Risk factors for hospital-acquired candidemia. Arch Intern Med 1989; 149: 2349-53
55. Beck-Sague CM, Jarvis WR. National Nosocomial Infection Surveillance System. Secular trends in the epidemiology of nosocomial fungal infections in the United States. J Infect Dis 1993; 167: 1247-51
56. Foran RM, Brett JL, Wulf PH. Evaluating the cost impact of intravenous antibiotic dosing frequencies. DICP 1991; 25: 546-51
57. Eisenberg JM, Koffer H, Click H, et al. What is the cost of nephrotoxicity? Ann Intern Med 1987; 107: 900-9
58. Bertino JS, Rodvold K, Destache CJ. Cost considerations in therapeutic drug monitoring of aminoglycosides. Clin Pharmacokinet 1994; 26: 71-81
59. Schaberg DR, Culver DH, Gaynes RP. Major trends in the microbial etiology of nosocomial infection. Am J Med 1991; 91: Suppl. 3B: 72S-5S
60. Kovorik JA, Yu VL. Antimicrobial therapy for Pseudomonas aeruginosa. Antimicrob Agents Chemother 1991; 35: 2167-72
61. Bodey GP, Bolivar R, Fainstein V, et al. Infections caused by Pseudomonas aeruginosa. Rev Infect Dis 1983; 5: 279-312
62. Kielfofner M, Atmar RL, Hamill RJ, et al. Life-threatening Pseudomonas infections in patients with human immunodeficiency virus infection. Clin Infect Dis 1992; 14: 403-11
63. Bodey GP, Jadeja L, Etling L. Pseudomonas bacteremia: Retrospective analysis of 410 episodes Arch Intern Med 1985; 145: 1621-9
64. Rains CP, Bryson HM, Peters DH. Ceftazidime: an update of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy. Drugs 1995; 49: 577-617
65. Armstrong D, Young LS, Meyer RD, et al. Infectious complications in neoplastic disease. Med Clin North Am 1971; 55: 729
66. Sanders JW, Powe NR, Moore RD. Ceftazidime monotherapy for empiric treatment of febrile neutropenic patients: a meta-analysis. J Infect Dis 1991 Nov; 164: 907-16
67. Johnson MP, Ramphal R. Beta-lactamase resistant Enterobacter bacteremia in febrile neutropenic patients receiving monotherapy. J Infect Dis 1990 Oct; 162: 981-3
68. Fink MP, Snydman DR, Niederman MS, et al. Treatment of severe pneumonia in hospitalized patients: results of a multicenter, randomized, double-blind trial comparing intravenous ciprofloxacin with imipenem-cilastatin. Antimicrob Agents Chemother 1994; 38: 547-57
69. EORTC International Antimicrobial Therapy Cooperative Group. Ceftazidime combined with short or long course of amikacin for empirical therapy of gram-negative bacteremia in cancer patients with granulocytopenia. N Engl J Med 1987; 317: 1692-8
70. Nicolau DP, Nightingale CH, Banevicius MA, et al. Serum bactericidal activity of ceftazidime: continuous infusion versus intermittent injections. Antimicrob Agents Chemother 1996; 40: 61-4
71. Cappelletty DM, Kang SL, Palmer SM, et al. Pharmacodynamics of ceftazidime administered as continuous infusion or intermittent bolus alone and in combination with single-daily dose amikacin against Pseudomonas aeruginosa in an in vitro infection model. Antimicrob Agents Chemother 1995; 39: 1797-801
72. Benko AS, Cappelletty DM, Kruse JA, et al. Continuous infusion versus intermittent administration of ceftazidime in critically ill patients with suspected gram-negative infection. Antimicrob Agents Chemother 1996; 40: 691-5
73. Dudley MN, Blaser J, Gilbert D, et al. Combination therapy with ciprofloxacin plus azlocillin against Pseudomonas aeruginosa: effect of simultaneous versus staggered administration in an in vitro model of infection. J Infect Dis 1991; 164: 499-506
74. Brouqui P, Rousseau MC, Stein A. et al. treatment of Pseudomonas aeruginosa-infected orthopedic prostheses with ceftazidime-ciprofloxacin antibiotic combination. Antimicrob Agents Chemother 1995; 39: 2423-5
75. Rybak MJ, Boike SC, Levine DP, et al. Clinical use and toxicity of high-dose tobramycin in patients with pseudomonal endocarditis. J Antimicrob Chemother 1986; 17: 115-20
76. Fong IW, Tomkins KB. Review of Pseudomonas aeruginosa meningitis with special emphasis on treatment with ceftazidime. Rev Infect Dis 1985; 7: 604-12
77. Chow JW, Fine MJ, Shales DM, et al. Enterobacter bacteremia: clinical features and emergence of antibiotic resistance during therapy. Ann Intern Med 1991; 115: 585-90
78. Urban C, Go E, Mariano N, et al. Effect of sulbactam on infections caused by imipenem-resistant Acinetobacter calcoaceticus biotype anitratus. J Infect Dis 1993; 167: 448-51
79. Mulligan ME, Murray-Leisure K, Rihner BS, et al. Methicillin-resistant Staphylococcus aureus: consensus review of the microbiology, pathogenesis, and epidemiology with implications for prevention and management. Am J Med 1993; 94: 313-25
80. Abrams B, Sklaver A, Hoffman T, et al. Single or combination therapy of staphylococcal endocarditis in intravenous drug abusers. Ann Intern Med 1979; 90: 789-91
81. Koreniowski O, Sande MA, National Collaborative Endocarditis Study Group. Combination antimicrobial therapy for Staphylococcus aureus endocarditis in patients addicted to parenteral drugs and in nonaddicts. Ann Intern Med 1982; 97: 496-503
82. Chambers HF, Miller RT, Newmann MD. Right-sided staphylococcus endocarditis in intravenous drug abusers: two-week combination therapy. Ann Intern Med 1988; 109: 619-24
83. Bayer AS. Infective endocarditis. Clin Infect Dis 1993; 17: 313-22
84. Chin NX, Neu HC. Combination of ofloxacin and other antimicrobial agents. J Chemother 1990; 2: 343-7
85. Kaatz GW, Seo SM, Barriere SL, et al. Ciprofloxacin and rifampin, alone and in combination for therapy of experimental Staphylococcus aureus endocarditis. Antimicrob Agents Chemother 1989; 33: 1184-7
86. Kang SL, Rybak MJ. Pharmacodynamics of RP 59500 alone and in combination with vancomycin against Staphylococcus aureus in an vitro-infected fibrin clot model. Antimicrob Agents Chemother 1995; 39: 1505-11
87. Dworkin RJ, Sande MA, Lee BL, et al. Treatment of right-sided Staphylococcus aureus endocarditis in intravenous drug abusers with ciprofloxacin and rifampin. Lancet 1989; 11: 1071-3
88. Faville RJ, Zaske DE, Kaplan EL, et al. Staphylococcus aureus endocarditis. JAMA 1978; 240: 1963-5
89. Levine DP, Fromm BS, Reddy BR. Slow response to vancomycin or vancomycin plus rifampin in methicillin-resistant Staphylococcus aureus endocarditis. Ann Intern Med 1991; 115: 674-80
90. Matsumoto JY, Wilson WR, Wright AJ, et al. Synergy of penicillin and decreasing concentrations of aminoglycosides against enterococci from patients with infective endocarditis. Antimicrob Agents Chemother 1980; 18: 944-7
91. Carrizosa J, Levison ME. Minimal concentrations of aminoglycoside that can synergize with penicillin in enterococcal endocarditis. Antimicrob Agents Chemother 1987; 31: 405-9
92. Thauvin C, Eliopoulos GM, Willey S, et al. Continuous-infusion ampicillin therapy of enterococcal endocarditis in rats. Antimicrob Agents Chemother 1987; 31: 139-43
93. Hindes RG, Willey SH, Eliopoulos GM, et al. Treatment of experimental endocarditis caused by a beta-lactamase producing strain of Enterococcus faecalis with high-level resistance to gentamicin. Antimicrob Agents Chemother 1989; 33: 1019-22
94. Moellering Jr RC. Emergence of enterococcus as a significant pathogen. Clin Infect Dis 1992; 14: 1173-8
95. Murray BE. The life and times of the enterococcus. Clin Microbiol Rev 1990; 3: 46-65
96. Centers for Disease Control and Prevention. Nosocomial enterococci resistant to vancomycin - United States, 1989-93. MMWR Morb Mortal Wkly Rep 1993; 42: 597-9
97. Arthur M, Molinas C, Bugg TDH, et al. Evidence for in vivo incorporation ot D-lactate into peptidoglycan precursors of vancomycin-resistant enterococci. Antimicrob Agents Chemother 1992; 36: 867-9
98. Arthur M, Courvalin P. Genetics and mechanisms ot glycopeptide resistance in enterococci. Antimicrob Agents Chemother 1993; 37: 1564-71
99. Williamson RC, Al-Obeid S, Shlaes JH, et al. Inducible resistance to vancomycin in Enterococcus faecium D366. J Infect Dis 1989; 159: 1095-104
100. Handwerger S, Perlman DC, Altarac D, et al. Concomitant high-level vancomycin and penicillin resistance in clinical isolates of enterococci. Clin Infect Dis 1992; 14: 655-61
101. Caron F, Carbon C, Gutman L. Triple-combination penicillinvancomycin-gentamicin for experimental endocarditis caused by a moderately penicillin- and highly glycopeptide-resistant isolate ot Enterococcus faecium. J Infect Dis 1991; 164: 888-93
102. Caron F, Pestel M, Kitzis MD, et al. Comparison of different β-lactam-glycopeptide-gentamicin combinations for an experimental endocarditis caused by a highly β-lactam-resistant and highly glycopeptide-resistant isolate of Enterococcus faecium. J Infect Dis 1995; 171: 106-12
103. Leclercq R, Bingen E, Su QH, et al. Effects of combinations of beta-lactams, daptomycin, gentamicin, and glycopeptides against glycopeptide-resistant enterococci. Antimicrob Agents Chemother 1991; 35: 92-8
104. Sahm DF, Koburov GT. In vitro activities of quinolones against enterococci resistant to penicillin-aminoglycosides synergy. Antimicrob Agents Chemother 1989; 13: 71-7
105. Landman D, Moharakai NK, Quale JM. Novel antibiotic regimens against Enterococcus faecium resistant to ampicillin, vancomycin, and gentamicin. Antimicrob Agents Chemother 1993; 376: 1904-8
106. French P, Ventuti E, Fraimow HS. In vitro activity of novobiocin against multiresistant strains of Enterococcus faecium. Antimicroh Agents Chemother 1993; 37: 2736-9
107. Chia JKS, Nakata MM, Park SS, et al. Use of bacitracin therapy for infection due to vancomycin-resistant Enterococcus faecium. Clin Infect Dis 1995; 21: 1520
108. Chant C, Rybak MJ. Quinupristin/dalfopristin (RP 59500): a new streptogramin antibiotic. Ann Pharmacother 1995; 29: 1022-7
109. Cerwinka S, Boinpart F, Kreter B, et al. Emergency use and accelerated development of Synercid (RP 59500) for treating vancomycin resistant Enterococcus faecium (VRHF) infections [abstract]. Presented at the Bacterial Multidrug Resistunce Meeting: overcoming the multidrug resistance challenge; 1995 Jan: Bethesda (MD)
110. Nicolau DP, Marangos MN, Nightingale CH, et al. Efficacy of vancomycin and teicoplanin alone and in combination with streptomycin in experimental low-level vancomycin-resistant VimB-type Enterococcus faecium endocarditis. Antimicroh Agents Chemother 1996; 40: 55-60